FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1622-1623 November 14, 2002 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Whyte, M. P. PubMed Citation

To the Editor: Whyte et al. (July 18 issue)¹ report that homozygous deletion of the gene encoding osteoprotegerin is a potential cause of juvenile Paget's disease in some Navajo patients. A deficiency of osteoprotegerin leads to unopposed effects of its ligand, receptor activator of nuclear factor B (RANK) ligand, resulting in enhanced osteoclastic bone resorption and profound bone loss. Since osteoprotegerin also serves as a receptor antagonist for tumor necrosis factor–related apoptosis-inducing ligand (TRAIL),² one cannot rule out the possibility that excessive TRAIL effects contributed to the skeletal phenotype.

Increased susceptibility to infectious and cardiovascular diseases in patients with juvenile . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.